The Center for Gene and Cellular Immunotherapy currently offers the following standard of care cellular immunotherapy options that are approved by the Food and Drug Administration (FDA):

Tescartus® (brexucabtagene autoleucel)

Approved by the FDA in July 2020 for use in adult patients diagnosed with relapsed or refractory mantle cell lymphoma (MCL). It is the first CAR-T approved for MCL and provides a very promising and effective option for patients with relapsed refractory MCL.

Kymriah™ (tisagenlecleucel)

Approved for use in adult patients with relapsed or refractory large B-cell lymphoma and in patients up to age 25 diagnosed with B-cell precursor acute lymphoblasticleukemia (ALL) that is refractory or in second or later relapse. When first approved by the FDA in 2017, it was the first gene and cellular therapy option available in the United States.

Yescarta® (axicabtagene ciloleucel)

Approved for use in adult patients diagnosed with diffuse large B-cell lymphoma who have failed at least two other treatments as well as for patients diagnosed with transformed follicular lymphoma and primary mediastinal B-cell lymphoma. CGCI investigators instrumental in the initial clinical trials leading to approval of axicabtagene ciloleucel. The Center also was one of the first 16 centers in the country to offer this immunotherapy to patients when it was approved by the FDA as a breakthrough therapy in 2017.

Breyanzi® (lisocabtagene maraleucel)

Approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

In addition, patients seen at Siteman Cancer Center/Barnes-Jewish Hospital have access to a wide variety of clinical trials.